Rallybio (RLYB) Change in Accured Expenses (2020 - 2026)
Rallybio (RLYB) posted Change in Accured Expenses of -$712000.0 for Q1 2026, down 2257.58% sequentially from $33000.0 in Q4 2025, and up 70.99% YoY from -$416408.0 in Q1 2025.
Rallybio (RLYB) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Rallybio has reported Change in Accured Expenses for 7 years, with the latest figure at -$712000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 70.99% year-over-year to -$712000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $593000.0 (up 108.39% YoY) and the FY2025 annual result came in at -$1.1 million, up 65.64% from the prior year.
- Change in Accured Expenses retreated to -$712000.0 in Q1 2026 per RLYB's latest filing, from $33000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.6 million in Q3 2022 and troughed at -$3.6 million in Q1 2023.
- A 5-year average of -$201529.4 and a median of -$350000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 316.01% in 2024, then soared 2796.43% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$841000.0 in 2022, then climbed by 18.31% to -$687000.0 in 2023, then tumbled by 102.77% to -$1.4 million in 2024, then soared by 102.37% to $33000.0 in 2025, then tumbled by 2257.58% to -$712000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$712000.0, $33000.0, and -$350000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -521,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -521,000.00 |
| Jun 30, 2026 | -521,000.00 |
| Mar 31, 2026 | -712,000.00 |
| Mar 31, 2026 | -712,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Sep 30, 2025 | -350,000.00 |
| Sep 30, 2025 | -350,000.00 |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.45 Mn |
| Dec 31, 2024 | -1.39 Mn |
| Dec 31, 2024 | -1.39 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 56,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |